✦ LIBER ✦

Editorial: Developing drugs for neglected diseases

✍ Scribed by N. J. White

Book ID: 110869888
Publisher: John Wiley and Sons
Year: 2006
Tongue: French
Weight: 39 KB
Volume: 11
Category: Article
ISSN: 1360-2276
DOI: 10.1111/j.1365-3156.2006.01597.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Editorial: Drug development for neglecte

Editorial: Drug development for neglected diseases: a public health challenge

✍ Angela Fehr; Petra Thürmann; Oliver Razum 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 449 KB

Drug discovery and development for negle

Drug discovery and development for neglected parasitic diseases

✍ Renslo, Adam R; McKerrow, James H 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 314 KB

Opening Opportunities for New Drugs Agai

Opening Opportunities for New Drugs Against Neglected Diseases

✍ Maria Paola Costi; Donatella Taramelli; Dolores González-Pacanowska 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

New drugs for neglected infectious disea

New drugs for neglected infectious diseases: Chagas' disease

✍ Fabiana S Machado; Herbert B Tanowitz; Mauro M Teixeira 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 117 KB

Orphan drug legislation: lessons for neg

Orphan drug legislation: lessons for neglected tropical diseases

✍ Stefano Villa; Amelia Compagni; Michael R. Reich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract In the last 20 years, orphan drug legislation (ODL) has been adopted in several countries around the world (USA, Japan, Australia, and the European Union) and has successfully promoted R&D investments to develop new pharmaceutical products for the treatment of rare diseases. Without the

FDA launches priority vouchers for negle

FDA launches priority vouchers for neglected-disease drugs

✍ Waltz, Emily 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 636 KB